Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma.
Lucarini V, Melaiu O, D'Amico S, Pastorino F, Tempora P, Scarsella M, Pezzullo M, De Ninno A, D'Oria V, Cilli M, Emionite L, Infante P, Di Marcotullio L, De Ioris MA, Barillari G, Alaggio R, Businaro L, Ponzoni M, Locatelli F, Fruci D. Lucarini V, et al. Among authors: melaiu o. J Exp Clin Cancer Res. 2022 Nov 17;41(1):326. doi: 10.1186/s13046-022-02525-9. J Exp Clin Cancer Res. 2022. PMID: 36397148 Free PMC article.
Expression status of candidate genes in mesothelioma tissues and cell lines.
Melaiu O, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddis R, Lucchi M, Pellegrini S, Gemignani F, Landi S. Melaiu O, et al. Mutat Res. 2015 Jan;771:6-12. doi: 10.1016/j.mrfmmm.2014.11.002. Epub 2014 Nov 13. Mutat Res. 2015. PMID: 25771974 Clinical Trial.
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, Vymetalkova V, Barone E, Paolicchi E, Corrado A, Lepori I, Dell'Anno I, Pellè L, Vodicka P, Mutti L, Foddis R, Cristaudo A, Gemignani F, Landi S. De Santi C, et al. Among authors: melaiu o. Occup Environ Med. 2017 Jun;74(6):456-463. doi: 10.1136/oemed-2016-104024. Epub 2017 Mar 25. Occup Environ Med. 2017. PMID: 28343162 Free article.
The regulatory roles of phosphatases in cancer.
Stebbing J, Lit LC, Zhang H, Darrington RS, Melaiu O, Rudraraju B, Giamas G. Stebbing J, et al. Among authors: melaiu o. Oncogene. 2014 Feb 20;33(8):939-53. doi: 10.1038/onc.2013.80. Epub 2013 Mar 18. Oncogene. 2014. PMID: 23503460 Review.
Risk of differentiated thyroid carcinoma and polymorphisms within the susceptibility cancer region 8q24.
Cipollini M, Figlioli G, Garritano S, Bramante S, Maiorano L, Gnudi F, Cecchini A, De Paola F, Damicis L, Frixa T, Landi D, Cancemi L, De Santi C, Melaiu O, Foddis R, Cristaudo A, Bonotti A, Romei C, Elisei R, Pellegrini G, Barale R, Gemignani F, Landi S. Cipollini M, et al. Among authors: melaiu o. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2121-5. doi: 10.1158/1055-9965.EPI-13-0790. Epub 2013 Sep 5. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 24008490
A Comprehensive Meta-analysis of Case-Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma.
Figlioli G, Elisei R, Romei C, Melaiu O, Cipollini M, Bambi F, Chen B, Köhler A, Cristaudo A, Hemminki K, Gemignani F, Försti A, Landi S. Figlioli G, et al. Among authors: melaiu o. Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):700-13. doi: 10.1158/1055-9965.EPI-15-0652. Epub 2016 Feb 3. Cancer Epidemiol Biomarkers Prev. 2016. PMID: 26843521
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma.
Pellé L, Cipollini M, Tremmel R, Romei C, Figlioli G, Gemignani F, Melaiu O, De Santi C, Barone E, Elisei R, Seiser E, Innocenti F, Zanger UM, Landi S. Pellé L, et al. Among authors: melaiu o. Arch Toxicol. 2016 Dec;90(12):3099-3109. doi: 10.1007/s00204-016-1660-8. Epub 2016 Jan 19. Arch Toxicol. 2016. PMID: 26783003
51 results